About Scioderm
Scioderm is a company based in Durham (United States) founded in 2012 was acquired by Amicus Therapeutics in August 2015.. Scioderm has raised $37 million across 3 funding rounds from investors including Amicus Therapeutics, Redmile Group and Morgenthaler. The company has 6 employees as of December 31, 2015. Scioderm operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others.
- Headquarter Durham, United States
- Employees 6 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Scioderm, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$37 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Series B
Dec 18, 2014
-
Investors
Amicus Therapeutics
& 3 more
-
Employee Count
6
as on Dec 31, 2015
-
Acquired by
Amicus Therapeutics
(Aug 31, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Scioderm
Scioderm has successfully raised a total of $37M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $20.0M
-
First Round
First Round
(25 Mar 2013)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2014 | Amount | Series B - Scioderm | Valuation |
investors |
|
| Apr, 2013 | Amount | Series A - Scioderm | Valuation |
investors |
|
| Mar, 2013 | Amount | Seed - Scioderm | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Scioderm
Scioderm has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Amicus Therapeutics, Redmile Group and Morgenthaler. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity investment firm
|
Founded Year | Domain | Location | |
|
Investments are made in US life sciences and energy companies.
|
Founded Year | Domain | Location | |
|
Operates as an employee-owned hedge fund focused on long/short equity strategies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Scioderm
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Scioderm
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Scioderm Comparisons
Competitors of Scioderm
Scioderm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Mirum Pharmaceuticals and Homology Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
|
| domain | founded_year | HQ Location |
Orally deliverable bradykinin B2 antagonists are developed for hereditary angioedema.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Scioderm
When was Scioderm founded?
Scioderm was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Scioderm located?
Scioderm is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is Scioderm a funded company?
Scioderm is a funded company, having raised a total of $37M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Mar 25, 2013.
How many employees does Scioderm have?
As of Dec 31, 2015, the latest employee count at Scioderm is 6.
What does Scioderm do?
Scioderm was founded in 2012 in Durham, United States, within the biotechnology sector. Topical products are developed to meet needs in treating chronic skin diseases. The lead product, SD-101, is advanced for managing skin manifestations of Epidermolysis Bullosa, a rare genetic connective tissue disorder appearing in early life. Operations focus on dermatological innovations for such conditions.
Who are the top competitors of Scioderm?
Scioderm's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Who are Scioderm's investors?
Scioderm has 4 investors. Key investors include Amicus Therapeutics, Redmile Group, Morgenthaler, and Technology Partners.